



(UBS)

Washington Weekly: Shutdown Threat, Again

19 December 2025, 19:22 UTC, written by UBS Editorial Team

There was some activity on expiring health care subsidies this week when four moderate House Republicans joined House Democrats on a discharge petition to force a vote on a three-year extension. This sets up a House vote (and likely passage) in January. With the support of these Republicans, the bill is expected to pass the House, but its prospects in the Senate are dim. John Nolan and the Governmental Affairs US team discuss this topic and others in this week's Washington Weekly.

Despite the momentum, the subsidies will expire at the end of this year and are unlikely to be extended next year (barring a wild card like President Trump calling for an extension).

Congress left town for the year having made little progress on government funding. It has the daunting task of trying to pass the remaining nine bills next month before a January 30 funding deadline. Congress may ring in the new year with the threat of another government shutdown.

With all of the political hand-wringing about affordability, one major and uncertain driver is tariffs. All eyes are on the Supreme Court and its decision on the Trump administration's use of emergency powers to apply broad-based "reciprocal" tariffs on US trading partners. The court is out until January 12 and likely will make a decision in the first few months of 2026. Whatever the Supreme Court decides, President Trump is likely to retain elevated tariffs in some form even with prevailing concerns around the country about affordability and inflation.

Health care Push Hits a Wall.

This educational report has been prepared by UBS Financial Services, Inc. Please see important disclaimers and disclosures at the end of the document.

The House this week had votes on some modest health care bills, but not on an extension of Affordable Care Act (ACA) subsidies. Frustrated by that, four moderate House Republicans joined House Democrats on a discharge petition to force a vote on renewing the ACA subsidies for three years. While this was a notable step, the bill won't receive a vote until January. With the support of these Republicans, the bill is expected to pass the House, but its prospects in the Senate are dim. A similar bill already failed to reach the needed 60-vote threshold (47 Democrats and 4 Republicans voted yes). Senate Republican leadership has shown little appetite for taking up the measure again. Despite the momentum, ACA subsidies will expire at the end of this year and are unlikely to be extended next year (barring a wild card like President Trump calling for an extension).

Shutdown Threat, Again.

Congress left town for the year having made little progress on government funding. As part of the end of the government shutdown, Congress passed three (Legislative Branch, Military Construction-Veterans Affairs and Agriculture) of the 12 government spending bills for fiscal year 2026. It has the daunting task of trying to pass the remaining nine bills next month before a January 30 funding deadline. In January, the Senate will try to pass a group of five spending bills, but there are concerns about overall spending levels and certain provisions in some of the larger and more contentious bills (particularly Defense and Labor-Health). The House is taking a different approach of trying to pass bills in groups of three, starting with those that are comparatively less controversial like Commerce, Energy, and Environment. With such little time to reconcile differences and pass these bills in January, Congress may resort to trying to extend current funding for most government agencies through another continuing resolution, whether to buy themselves some more time or to throw in the towel and extend it to the end of the year. Congress may ring in the new year with the threat of another government shutdown.

2026 Political Winds.

With the calendar about to turn, both parties are sharpening their messages for the midterm elections. Democrats are focused on "affordability," a catchall for concerns about rising costs on groceries, rent, childcare, and health care. They believe the theme powered recent strong performances in off-year elections in Virginia, New Jersey, and elsewhere. However, while polling shows that voters are angry about high prices and are souring on President Trump's economic policies, they still aren't fully sold on Democrats as the alternative. This rings especially true among moderates and white working-class voters in states like Alaska, Iowa, and Ohio where Democrats will need to win difficult Senate races if they hope to flip the upper chamber. Meanwhile, Republicans are leaning into economic stewardship and cultural fights, hoping to keep their gains among Latinos and younger voters who remain skeptical of both parties. Recent elections show momentum for Democrats going into the midterms, but it remains to be seen how much they can capitalize on prevailing economic anxieties.

For more on topics under the dome, see the [latest Washington Weekly](#).

Disclaimer

Hong Kong / Singapore: For Global Wealth Management clients of UBS AG Singapore / Hong Kong branch, please refer to the [HK/SG Marketing Material Disclaimer](#).

This document is prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland), its subsidiaries or its affiliates ("UBS"), part of UBS Group AG ("UBS Group"). UBS Group includes former Credit Suisse AG, its subsidiaries, branches and affiliates. In the USA, UBS Financial Services Inc. is a subsidiary of UBS AG and a member of FINRA/SIPC. Additional Disclaimer relevant to Credit Suisse Wealth Management follows at the end of this section.

This document and the information contained herein are provided solely for your information and UBS marketing purposes. Nothing in this document constitutes investment research, investment advice, a sales prospectus, or an offer or solicitation to engage in any investment activities. This document is not a recommendation to buy or sell any security, investment instrument, or product, and does not recommend any specific investment program or service.

Information contained in this document has not been tailored to the specific investment objectives, personal and financial circumstances, or particular needs of any individual client. Certain investments referred to in this document may not be suitable or appropriate for all investors. In addition, certain services and products referred to in the document may be subject to legal restrictions and/or license or permission requirements and cannot therefore be offered worldwide on an unrestricted basis. No offer of any product will be made in any jurisdiction in which the offer, solicitation, or sale is not permitted, or to any person to whom it is unlawful to make such offer, solicitation, or sale.

Although all information and opinions expressed in this document were obtained in good faith from sources believed to be reliable, no representation or warranty, express or implied, is made as to the document's accuracy, sufficiency, completeness or reliability. All information and opinions expressed in this document are subject to change without notice and may differ from opinions expressed by other business areas or divisions of UBS Group. UBS is under no obligation to update or keep current the information contained herein. **The views and opinions expressed in this material by third parties are not those of UBS.** Accordingly, UBS does not accept any liability over the content shared by third parties or any claims, losses or damages arising from the use or reliance of all or any part thereof.

All pictures or images ("images") herein are for illustrative, informative or documentary purposes only and may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. Unless expressly stated, no relationship, association, sponsorship or endorsement is suggested or implied between UBS and these third parties. Any charts and scenarios contained in the document are for illustrative purposes only. Some charts and/or performance figures may not be based on complete 12-month periods which may reduce their comparability and significance. Historical performance is no guarantee for, and is not an indication of future performance.

Nothing in this document constitutes legal or tax advice. UBS and its employees do not provide legal or tax advice. This document may not be redistributed or reproduced in whole or in part without the prior written permission of UBS. To the extent permitted by the law, neither UBS, nor any of its directors, officers, employees or agents accepts or assumes any liability, responsibility or duty of care for any consequences, including any loss or damage, of you or anyone else acting, or refraining to act, in reliance on the information contained in this document or for any decision based on it.

Additional Disclaimer relevant to Credit Suisse Wealth Management: Except as otherwise specified herein and/or depending on the local entity from which you are receiving this document, this document is distributed by UBS Switzerland AG, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). Your personal data will be processed in accordance with the Credit Suisse privacy statement accessible at your domicile through the official Credit Suisse website <https://www.credit-suisse.com>. In order to provide you with marketing materials concerning our products and services, UBS Group AG and its subsidiaries may process your basic personal data (i.e. contact details such as name, e-mail address) until you notify us that you no longer wish to receive them. You can optout from receiving these materials at any time by informing your Relationship Manager.

Please visit <https://www.ubs.com/global/en/wealth-management/insights/chief-investment-office/marketing-material-disclaimer.html> to read the full legal disclaimer applicable to this document.

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

Important information

As a firm providing wealth management services to clients, UBS Financial Services, Inc is registered with the U.S. Securities and Exchange Commission (SEC) as an investment adviser and a broker-dealer, offering both investment advisory and brokerage services. Advisory services and brokerage services are separate and distinct, differ in material ways and are governed by different laws and separate contracts. It is important that you carefully read the agreements and disclosures UBS provides to you about the products or services offered. For more information, please see www.ubs.com/workingwithus

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved. UBS Financial Services Inc. is a subsidiary of UBS AG. Member FINRA/SIPC.

There are two sources of UBS research. Reports from the first source, UBS CIO Global Wealth Management, are designed for individual investors and are produced by UBS Global Wealth Management (which includes UBS Financial Services Inc. and UBS International Inc.). The second research source is UBS Group Research, whose primary business focus is institutional investors. The two sources operate independently and may therefore have different recommendations. The various research content provided does not take into account the unique investment objectives, financial situation or particular needs of any specific individual investor. If you have any questions, please consult your Financial Advisor. UBS Financial Services Inc. is a subsidiary of UBS AG and an affiliate of UBS International Inc.